Go Pro
NASDAQ:NYXH

Nyxoah Q4 2025 Earnings Report

Nyxoah logo
$1.45 +0.18 (+14.17%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.01 (+0.69%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nyxoah EPS Results

Actual EPS
-$0.69
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
$6.62 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nyxoah's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Nyxoah Earnings Headlines

Nyxoah Names Loic Moreau Interim CFO as John Landry Steps Down
Iran War WARNING: Something Just Changed
A powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.tc pixel
Nyxoah Announces Chief Financial Officer Transition
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH) is a medical technology company focused on developing treatments for obstructive sleep apnea (OSA), a sleep-related breathing disorder caused by repeated airway obstruction during sleep. The company is headquartered in Mont-Saint-Guibert, Belgium, and trades on Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to activate the nerves controlling the tongue and upper-airway muscles, helping maintain an open airway during sleep. Unlike some competing approaches, Genio is designed without an implanted chest generator and uses an external wearable activation component.

The company has pursued regulatory approvals and commercial expansion in Europe and the United States, with its activities focused on markets where the Genio system is authorized for use. Nyxoah’s technology is aimed primarily at patients who cannot tolerate or do not adequately respond to continuous positive airway pressure therapy. Olivier Taelman serves as Nyxoah’s chief executive officer.

View Nyxoah Profile